Table 3.

Adverse events that occurred during the study

	Pelubiprofen (n =77)		Celecoxib (n =68)
	Patients, n (%)	Events, n	Patients, n (%)	Events, n	p-value*
Total adverse events	39 (50.6)	62	25 (36.8)	33	0.09
Gastrointestinal	21 (27.3)	29	7 (10.3)	8	0.01
Anorexia	2 (2.6)	2	1 (1.47)	1
Nausea	2 (2.6)	3	3 (4.41)	3
Vomiting	1 (1.3)	1	1 (1.47)	1
Indigestion	3 (3.9)	2	1 (1.47)	1
Epigastric discomfort	4 (5.2)	4	0 (0.0)	0
Abdominal pain	10 (13.0)	10	2 (2.94)	2
Diarrhea	4 (5.19)	5	0 (0.0)	0
Constipation	2 (2.6)	2	0 (0.0)	0
Systemic	11 (14.3)	13	4 (5.9)	4	0.10
Facial edema	5 (6.49)	5	1 (1.5)	1
Edema	4 (5.19)	5	1 (1.5)	1
Chest discomfort	1 (1.3)	1	0 (0.0)	0
Nipple pain	0 (0.0)	0	1 (1.5)	1
Weight gain	0 (0.0)	0	1 (1.5)	1
Pain	1 (1.3)	1	0 (0.0)	0
Fatigue	1 (1.3)	1	0 (0.0)	0
Anemia	0 (0.0)	0	1 (1.5)	1	0.29
Respiratory	6 (7.8)	6	4 (5.9)	4	0.65
Nervous system	2 (2.6)	2	4 (5.9)	6	0.32
Skin and appendage	3 (3.9)	4	1 (1.5)	1	0.37
Musculoskeletal	1 (1.3)	1	2 (2.9)	2	0.49
Hepatobiliary	1 (1.3)	1	1 (1.5)	2	0.92
Reproductive system	1 (1.3)	1	1 (1.5)	2	0.92
Cardiovascular	1 (1.3)	1	1 (1.5)	1	0.92
Infection	0 (0.0)	0	1 (1.5)	1	0.29
Eye	1 (1.3)	1	0 (0.0)	0	0.35
Urinary	1 (1.3)	1	0 (0.0)	0	0.35
Psychiatric	1 (1.3)	2	0 (0.0)	0	0.35
Peripheral vascular	0 (0.0)	0	1 (1.5)	1	0.29

*p-value by the chi-square test: difference between the proportions of patients that developed an adverse event.